ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2634

Sex differences in medication discontinuation in axial spondyloarthritis
Abstract Number: 0873

Sex Differences in Proteomic Profiles and the Impact of Deucravacitinib Treatment in Patients with Active Psoriatic Arthritis: A Pooled Phase 3 Analysis
Abstract Number: 0755

Sex Differences in Subtypes of Vascular Involvement and Clinical Manifestations in Giant Cell Arteritis
Abstract Number: 1793

Sex-associated changes to synovial macrophages in the aging joint
Abstract Number: 1935

Sex-associated disparities in industry payments to US authors in high-impact rheumatology journals correlate with author impact
Abstract Number: 1062

Sex-related differences in clinical presentation and patient-reported burden in chronic back pain: Are these findings specific to axSpA? Results from the SHERPAS Cohort
Abstract Number: 1885

Sex-specific Associations of Anthropometrics, Smoking and Eduction with the Risk of Rheumatoid Athritis: A Nested Case-Control Study
Abstract Number: 1817

Sex-specific mechanisms associated with female childhood-onset systemic lupus erythematosus revealed by transcriptomic analysis of transgender adolescents undergoing gender-affirming sex hormone therapy.
Abstract Number: 2316

Sexual Dysfunction in Women with Axial Spondyloarthritis: A Meta-Analysis of FSFI Total and Domain Scores
Abstract Number: 1603

SGLT-2 Inhibitors are Associated with Lower Risk of End Stage Renal Disease (ESRD) and Lower Mortality in ANCA-associated Vasculitis With Kidney Involvement
Abstract Number: 2438

SGLT2 Inhibitors in SLE: Impact on Pulmonary Hypertension, Mortality, and Renal Outcomes
Abstract Number: 0840

Shared and Distinct Urinary Proteomic Signatures of Lupus Nephritis and Other Glomerular Diseases
Abstract Number: 1865

Shared and unique molecular signatures across different autoantibody groups in systemic sclerosis: a multi-omics analysis
Abstract Number: 1266

Shared Decision Making in Rheumatoid Arthritis: Is RA disease activity associated with patient reported measures of shared decision making pre-SDM intervention?
Abstract Number: 0789

Short Form 36 (SF-36) Health Survey Questionnaire in Health-Related Quality of Life Assessment in Patients with Inflammatory Myopathies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].